北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 心血管内科  > 期刊论文
学科主题: 临床医学
题名:
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
作者: Holman, Rury R.1; Bethel, Mary A.1; Chan, Juliana C. N.2; Chiasson, Jean-Louis3; Doran, Zoe1; Ge, Junbo4; Gerstein, Hertzel5,6,7; Huo, Yong8; McMurray, John J.9; Ryden, Lars10; Liyanage, Winitha1; Schroeder, Stefan11; Tendera, Michal12; Theodorakis, Michael J.1; Tuomilehto, Jaakko13,14,15; Yang, Wenying16; Hu, Dayi17; Pan, Changyu18; ACE Study Grp
刊名: AMERICAN HEART JOURNAL
发表日期: 2014-07-01
DOI: 10.1016/j.ahj.2014.03.021
卷: 168, 期:1, 页:23-29
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Cardiac & Cardiovascular Systems
研究领域[WOS]: Cardiovascular System & Cardiology
关键词[WOS]: IMPAIRED GLUCOSE-TOLERANCE ; TYPE-2 DIABETES-MELLITUS ; OXIDATIVE STRESS ; POSTCHALLENGE HYPERGLYCEMIA ; POSTPRANDIAL HYPERGLYCEMIA ; ENDOTHELIAL DYSFUNCTION ; COAGULATION ACTIVATION ; MYOCARDIAL-INFARCTION ; PREVENTION PROGRAM ; DISEASE
英文摘要:

Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an a-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.

语种: 英语
项目资助者: Bayer
WOS记录号: WOS:000338748800005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65854
Appears in Collections:北京大学第一临床医学院_心血管内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Univ Oxford, Diabet Trials Unit, Oxford, England
2.Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
3.Univ Montreal, Dept Med, CRCHUM, Montreal, PQ H3C 3J7, Canada
4.Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China
5.McMaster Univ, Dept Med, Hamilton, ON, Canada
6.McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
7.Hamilton Hlth Sci, Hamilton, ON, Canada
8.Peking Univ, Hosp 1, Dept Cardiol, Beijing 100871, Peoples R China
9.Univ Glasgow, Inst Cardiovasc Med Sci, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
10.Karolinska Univ Hosp Solna, Cardiol Unit, Stockholm, Sweden
11.Bayer Pharma AG, Bayer Healthcare, Berlin, Germany
12.Med Univ Silesia, Div Cardiol 3, Katowice, Poland
13.Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria
14.King Abdulaziz Univ, Jeddah 21413, Saudi Arabia
15.China Japan Friendship Hosp, Beijing, Peoples R China
16.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
17.Natl Inst Hlth & Welf, Diabet Prevent Unit, Helsinki, Finland
18.Peoples Liberat Army Gen Hosp, Dept Endocrinol, Beijing, Peoples R China

Recommended Citation:
Holman, Rury R.,Bethel, Mary A.,Chan, Juliana C. N.,et al. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial[J]. AMERICAN HEART JOURNAL,2014,168(1):23-29.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Holman, Rury R.]'s Articles
[Bethel, Mary A.]'s Articles
[Chan, Juliana C. N.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Holman, Rury R.]‘s Articles
[Bethel, Mary A.]‘s Articles
[Chan, Juliana C. N.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace